(CercleFinance.com) – Guerbet, a specialist in contrast products for medical imaging, reported on Friday quarterly sales below expectations, with production delays having notably penalized its sales in the United States.
The maker of pharmaceuticals and medical devices reported this morning a turnover of 181.1 million euros for the first three of the year, up 2.7% compared to the figure of last year. business for the 1st quarter of 2021 (176.3 million).
For comparison, analysts expected a figure of 201 million euros.
In its press release, Guerbet attributes its poor performance to production delays at its North Carolina site, linked to local tensions in the labor market.
However, the group ensures that these delays are now being absorbed and that activity will catch up during the second half of the year.
Guerbet thus reaffirms its ambitions for the 2022 financial year, anticipating further growth in its turnover, between 2% and 4% on a like-for-like basis and at constant exchange rates.
In terms of profitability, he says he is aiming for an operating margin (Ebitda) “at least identical” to that of 2021, citing the inflationary context of the moment.
Following this publication, the action yielded 4% Friday at midday.